Acute Myeloid Leukemia in Adults (2nd Edition)

Dear Colleagues,

Acute myeloid leukemia is the most common type of leukemia in adults. It is caused by the acquisition of somatic mutations in hematopoietic stem and progenitor cells mediating their transformation to malignant cells that dominate the bone marrow. Despite extensive investigation of the molecular biology of AML and the introduction of numerous novel agents and combinational approaches for the treatment of this disease, AML patient outcomes—particularly for older individuals and those with antecedent myeloid neoplasms—remain poor. A deeper understanding of the molecular pathways driving AML growth and treatment resistance is needed to guide the development of new therapies, especially for resistant and relapsed forms of AML. This can be achieved by collaborative approaches in AML research and better insight into patterns of resistance to current therapeutic approaches.

This Special Issue will highlight recent discoveries in AML biology, the current therapeutic landscape, and possible mechanisms of resistance to existing treatments. Contributions may include basic, translational, and clinical studies, with particular emphasis on relapsed and treatment-resistant AML.

Dr. Theodoros Karantanos
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.